doi: 10.25005/2074-0581-2015-17-3-77-82
Evaluation of methotrexate use for patients with rheumatoid arthritis during implementation of «Treat to Target» strategy in real clinical practice

H.R. Makhmudov, Yo.U. Saidov, R.N. Zubaidov

Chair of Propaedeutics of Internal Diseases Avicenna TSMU

In the articleare analyzed, evaluated and presented the results of efficacy and safety of oral and parenteral methotrexate use in 57 patients with active rheumatoid arthritis (RA). Unlike to oral intake of methotrexate, parenteral its application in an adequate dose (15-20 mg / week) in combination with low doses of glucocorticoids (<10 mg / day) in patients with RA is associated with a more marked and stable clinical improvement and greater frequency of low activity and clinical remission (12,3% and 42,4%, 16,0% and 38,1%, respectively).

Thus, the use of parenteral methotrexate with rapid escalation of dose under careful monitoring of the therapy effectiveness and activity of RA and the improvement of patients’ compliance is the most important event in the practical implementation of the strategy «Treat to Target» (T2T).

Keywords: rheumatoid arthritis, methotrexate, the strategy of «Treat to Target».

Download file:

Materials on the topic: